Cas:56187-47-4 Cefazedone manufacturer & supplier

Chemical Name:Cefazedone

CAS.NO:56187-47-4

Synonyms:Cefazedonum;Refosporen;Cefazedone [INN:BAN];Cefazedonum [INN-Latin];3-(5-Methyl-1,3,4-thiadiazolyl-2-mercaptomethyl)-7-(3,5-dichloro-4-pyridon-1-ylacetamido)-3-cephem-4-carboxylic Acid;(6R,7R)-7-{[(3,5-Dichloro-4-oxopyridin-1(4H)-yl)acetyl]amino}-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;Cefazedone;(6R,7R)-7-{[(3,5-Dichloro-4-oxo-1(4H)-pyridinyl)acetyl]amino}-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;(6R)-7t-[2-(3,5-dichloro-4-oxo-4H-pyridin-1-yl)-acetylamino]-3-(5-methyl-[1,3,4]thiadiazol-2-ylsulfanylmethyl)-8-oxo-(6rH)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid;5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[2-(3,5-dichloro-4-oxo-1(4H)-pyridinyl)acetyl]amino]-3-[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-, (6R,7R)-;MFCD01682029;Cefazedona;Refosporene;Cefazedona [INN-Spanish]

Molecular Formula:C₁₈H₁₅Cl₂N₅O₅S₃

Molecular Weight:548.443

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.8±0.1 g/cm3

Index of Refraction:1.761

PSA:213.33000

Exact Mass:546.961243

LogP:0.92

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Cefazedonum chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Cefazedona [INN-Spanish] physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(6R)-7t-[2-(3,5-dichloro-4-oxo-4H-pyridin-1-yl)-acetylamino]-3-(5-methyl-[1,3,4]thiadiazol-2-ylsulfanylmethyl)-8-oxo-(6rH)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid Use and application,(6R)-7t-[2-(3,5-dichloro-4-oxo-4H-pyridin-1-yl)-acetylamino]-3-(5-methyl-[1,3,4]thiadiazol-2-ylsulfanylmethyl)-8-oxo-(6rH)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid technical grade,usp/ep/jp grade.

Related News: Analysts at Jefferies, meanwhile, said the FDA accelerated approval for Aduhelm, which was based on a surrogate endpoint of amyloid beta plaque reduction (and not clinical benefit) “has implications for ongoing AD studies,” most notably, it reckons, for Roche’s phase 3 GRADUATE test for its anti-amyloid-beta candidate gantenerumab, “as a much lower hurdle than demonstrating clear cognitive benefit” has now become precedent. Jefferies, still cautious, said it remains “unclear what stance FDA may take for the field if GRADUATE fails on cognition despite significant Abeta reductions,” but says it’s probably not going to revive Roche-AC Immune’s anti-amyloid-beta candidate crenezumab, which saw its late-stage CREAD trials discontinued for futility but which is currently in an Alzheimer’s prevention study. Cefazedone manufacturer GlaxoSmithKline (GSK) is at the bottom of the top 20 list with the lowest percentage R&D spend/annual revenue at 12%.�� Cefazedone supplier At present, Teva can produce more than 300 generic drugs, and the API department has approximately 650 authorized patents and patent applications worldwide. It is also the generic drug company with the most challenges in patenting ParagraphIV in the world. Cefazedone vendor Australia’s ban followed an earlier move by the US Friday to deny entry to foreign nationals who have traveled in China in the last 14 days. Cefazedone factory Covington has handled dozens of cases for Lilly over the past 20 years, according to the Westlaw database of legal cases and press releases, including intellectual property matters, personal injury lawsuits and class actions.